Choline Source
Citicoline
Strong EvidenceDecades of clinical use in stroke and vascular cognitive impairment give citicoline an unusually solid tolerability record; the case for cognitive gain in healthy adults is much weaker than that history suggests. By population: a Cochrane review of 14 placebo-controlled trials in older people with chronic cerebral disorders, most lasting 20 days to 3 months, found benefit on memory and behaviour but none on attention (Fioravanti 2005). In 100 healthy adults aged 50–85 with age-associated memory impairment, 500 mg a day for 12 weeks improved episodic and composite memory against placebo (Nakazaki 2021); in 75 healthy adolescent males, 250 or 500 mg for 28 days improved attention and psychomotor speed (McGlade 2019). The largest trial was negative: in 2,298 patients with acute ischaemic stroke, 2,000 mg a day for six weeks gave the same 90-day recovery as placebo and the trial was stopped for futility (Dávalos 2012). Against alpha-GPC, citicoline carries less choline per gram but has the healthier-adult trials and no comparable safety signal; phosphatidylserine targets the same older, memory-complaint group with a smaller trial; ALCAR complements it rather than replacing it. Verdict: a sensible choline source at 250–500 mg a day, with modest, population-specific evidence — not a demonstrated enhancer for healthy young adults.
Recommended Dose
250–500 mg daily
Timing
Morning with food
Mechanism of Action
Citicoline is CDP-choline (cytidine 5'-diphosphocholine), the body's own intermediate in making phosphatidylcholine, the main phospholipid of nerve-cell membranes; it is sold as a supplement and prescribed as a drug in several European countries. Swallowed, it is split into two building blocks. When twelve adults took 500, 2,000 and 4,000 mg in random order, plasma choline rose with the dose and stayed raised for 5 to 10 hours, and plasma uridine rose by 70–90% after 500 mg and 100–120% after 2,000 mg, with no further gain at 4,000 mg; cytidine, the route seen in rats, was barely detectable (Wurtman 2000). So in people the working substrates are choline, which feeds both membrane synthesis and acetylcholine, and uridine, which can enter the brain and be converted into the nucleotides that membrane synthesis needs.
Side Effects & Safety
Well-tolerated at recommended doses. Rare headache, insomnia, or GI discomfort. Slight stimulatory effect — avoid late-day dosing. In the 2,298-patient stroke trial, adverse-event rates did not differ from placebo at 2,000 mg a day (Dávalos 2012), and an open Italian study of 349 older adults with mild vascular cognitive impairment recorded no adverse events over nine months at 1,000 mg a day (Cotroneo 2013).
Do not use / talk to a doctor first
- Known hypersensitivity to citicoline
Interactions
Levodopa
Commonly assumed to be a hazard, and it is not one on the available evidence - citicoline has been used ALONGSIDE levodopa therapeutically in Parkinson's disease rather than avoided with it. If you take levodopa, discuss it with your neurologist, because the two are being used for related purposes, not because a dangerous interaction is documented
Source: Effects of choline-containing phospholipids on the neurovascular unit, PMC9541750
Meclofenoxate (centrophenoxine)
Both raise choline availability, so combining them is redundant rather than dangerous
Source: mechanistic
Pregnancy & breastfeeding
Not adequately studied in pregnancy or breastfeeding. Not recommended without medical advice.
Who should avoid / see a doctor
There is no strong contraindication to state here, and inventing one would be worse than saying so. The honest caution is narrower: if you take levodopa or any other Parkinson's medication, raise it with your neurologist, and stop if you get headache or insomnia rather than escalating the dose.
Synergies
Used in These Stacks
See Citicoline inside a full protocol — the stack pages cover when and why to combine it.
Best Products
Partner offers
Paid placements. We earn a commission if you buy through these links, at no extra cost to you — it does not change what we write. These are the seller’s own products and claims, not ours, and nothing here is medical advice. Speak to a clinician before starting any supplement.
References
- 1.Effects of choline containing phospholipids on the neurovascular unit: a review — Review of choline-containing phospholipids including citicoline, covering their therapeutic use in vascular cognitive impairment and their role alongside standard therapy. (narrative review)
- 2.Wurtman 2000, Biochem Pharmacol — 12 mildly hypertensive but otherwise healthy fasting adults, randomised crossover: oral citicoline 500, 2,000 and 4,000 mg raised plasma choline dose-dependently (elevated for 5, 8 and 10 h) and plasma uridine by 70–90% (500 mg) and 100–120% (2,000 mg), with no further rise at 4,000 mg; plasma cytidine was not reliably detectable.
- 3.Fioravanti 2005, Cochrane Database Syst Rev — Cochrane review of 14 double-blind placebo-controlled trials of CDP-choline in older people with chronic cerebral disorders (subjective memory complaints to vascular dementia), most 20–30 days to 3 months: no evidence of benefit on attention; evidence of benefit on memory and behaviour; well tolerated. (the principal reviewer was an investigator in some included trials)
- 4.Nakazaki 2021, J Nutr — 100 healthy adults aged 50–85 with age-associated memory impairment, randomised double-blind: citicoline 500 mg/day for 12 weeks improved episodic memory (paired-associate test, p=0.0025) and composite memory (p=0.0052) versus placebo.
- 5.McGlade 2019, J Atten Disord — 75 healthy adolescent males randomised to 250 or 500 mg citicoline (Cognizin) or placebo for 28 days: improved attention (p=0.02) and psychomotor speed (p=0.03) versus placebo. (three co-authors list Kyowa Hakko affiliations)
- 6.Dávalos 2012, Lancet — ICTUS: 2,298 patients with moderate-to-severe acute ischaemic stroke randomised to citicoline (2,000 mg/day, intravenous then oral, 6 weeks) or placebo; global recovery at 90 days was similar (OR 1.03, 95% CI 0.86–1.25) and the trial was stopped for futility; no difference in safety outcomes or adverse events. (funded by Ferrer Grupo)
- 7.Cotroneo 2013, Clin Interv Aging — IDEALE: open multicentre study of 349 adults aged 65+ with mild vascular cognitive impairment; 265 took oral citicoline 500 mg twice daily for 9 months, 84 untreated controls. MMSE scores stayed stable on citicoline with a significant difference from controls at 3 and 9 months; no adverse events recorded. (open-label, no placebo arm)
